Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report

Wang,Lina; Ni,Dawei; Zhong,Lin; Wang,Jianbo

doi:10.3892/ol.2017.7165

Familial genetic tuberous sclerosis complex associated with bilateral giant renal angiomyolipoma: A case report

Authors:
- Lina Wang
- Dawei Ni
- Lin Zhong
- Jianbo Wang
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/ol.2017.7165
Pages: 7099-7106
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disease involving multiple organs, but there are a limited number of reports on family TSC. In the present report, a case of a 52‑year‑old female with a familial genetic TSC, associated with bilateral giant renal angiomyolipoma, was described. The mother, second elder brother and daughter of the patient all exhibited TSC, but the clinical manifestations, and therapeutic prognosis between the family members were not the same. The present case report aimed at identifying an effective diagnostic method and treatment through additional study of familial genetic TSC, in order to prolong and improve the quality of life for patients with TSC. According to the present case and relevant literature reviews, it is suggested that fetal gene detection during pregnancy could prevent the passing of this disease onto further generations. Furthermore, early application of drug treatment may control the development of the disease in diagnosed patients. The combination of classical treatments with a small dose of mammalian target of rapamycin inhibitors is the typical recommendation, which may control the development of the disease more effectively and decrease adverse side‑effects.

View Figures

View References

1	Zhang Y, Gan J, Pu Z, Xu Mm, Wang Lf, Li Yh and Liu Zg: TSC1 R509X Mutation in a chinese family with tuberous sclerosis complex. Neuromolecular Med. 17:202–208. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cabrera-López C, Bullich G, Marti T, Català V, Ballarín J, Bissler JJ, Harris PC, Ars E and Torra R: Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Med Genet. 16:392015. View Article : Google Scholar : PubMed/NCBI
3	Hallett L, Foster T, Liu Z, Blieden M and Valentim J: Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: Systematic review. Curr Med Res Opin. 27:1571–1583. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hyman MH and Whittemore VH: National Institutes of Health consensus conference: Tuberous sclerosis complex. Arch Neurol. 57:662–665. 2000. View Article : Google Scholar : PubMed/NCBI
5	Rabito MJ and Kaye AD: Tuberous sclerosis complex: Perioperative considerations. Ochsner J. 14:229–239. 2014.PubMed/NCBI
6	Wang GX, Wang DW, Yi CY, Qu JS and Wang YL: Mutational analyses of the TSC1 and TSC2 genes in cases of tuberous sclerosis complex in Chinese Han children. Genet Mol Res. 12:1168–1175. 2013. View Article : Google Scholar : PubMed/NCBI
7	Northrup H and Krueger DA: International Tuberous Sclerosis Complex Consensus Group: Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 49:243–254. 2013. View Article : Google Scholar : PubMed/NCBI
8	Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D and van den Ouweland A: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 13:731–741. 2005. View Article : Google Scholar : PubMed/NCBI
9	van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 277:805–808. 1997. View Article : Google Scholar : PubMed/NCBI
10	Habib SL: Tuberous sclerosis complex and DNA repair. Adv Exp Med Biol. 685:84–94. 2010. View Article : Google Scholar : PubMed/NCBI
11	Inoki K, Corradetti MN and Guan K L: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 37:19–24. 2005. View Article : Google Scholar : PubMed/NCBI
12	Henske EP, Rasooly R, Siroky B and Bissler J: Tuberous sclerosis complex, mTOR, and the kidney: Report of an NIDDK-sponsored workshop. Am J Physiol Renal Physiol. 306:F279–F283. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yi L, Guo F and Zhang YB: Diagnosis and analysis of cases of tuberous sclerosis. J Clin Exp Med. 10:819–822. 2015.(In Chinese).
14	Krummel T, Garnon J, Lang H, Gangi A and Hannedouche T: Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition. BMC Urol. 14:772014. View Article : Google Scholar : PubMed/NCBI
15	Curatolo P and Moavero R: mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol. 10:404–415. 2012. View Article : Google Scholar : PubMed/NCBI
16	Staehler M, Sauter M, Helck A, Linsenmaier U, Weber L, Mayer K and Fischereder M: Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis. Int Urol Nephrol. 44:1657–1661. 2012. View Article : Google Scholar : PubMed/NCBI
17	Sasongko TH, Ismail NF and Zabidi-Hussin Z: Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev. 7:CD0112722016.PubMed/NCBI
18	Peces R, Cuestalópez E, Peces C and Selgas R: Giant bilateral renal angiomyolipomas and lymphangioleiomyomatosis presenting after two successive pregnancies successfully treated with surgery and rapamycin. ScientificWorldJournal. 11:2115–2123. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hallett L, Foster T, Liu Z, Blieden M and Valentim J: Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: Systematic review. Curr Med Res Opin. 27:1571–1583. 2011. View Article : Google Scholar : PubMed/NCBI
20	Crino PB, Nathanson KL and Henske EP: The tuberous sclerosis complex. N Engl J Med. 355:1345–1356. 2006. View Article : Google Scholar : PubMed/NCBI
21	O'Callaghan FJ, Noakes MJ, Martyn CN and Osborne JP: An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 94:853–857. 2004. View Article : Google Scholar : PubMed/NCBI
22	Mascarenhas R and McLaughlin P: Haemorrhage from angiomyolipoma of kidney during pregnancy-a diagnostic dilemma. Ir Med J. 94:83–84. 2001.PubMed/NCBI
23	Raft J, Lalot JM, Meistelman C and Longrois D: Influence of pregnancy on renal angiomyolipoma. Gynecol Obstet Fertil. 33:898–906. 2005.(In French). View Article : Google Scholar : PubMed/NCBI
24	Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Kwon ED and Leibovich BC: Hormone receptor expression in renal angiomyolipoma: Clinicopathologic correlation. Urology. 72:927–932. 2008. View Article : Google Scholar : PubMed/NCBI
25	Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al: Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 381:817–824. 2013. View Article : Google Scholar : PubMed/NCBI
26	Franz DN: Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 7:211–221. 2013.PubMed/NCBI
27	Roa J, Garcia-Galiano D, Castellano JM, Gaytan F, Pinilla L and Tena-Sempere M: Metabolic control of puberty onset: New players, new mechanisms. Mol Cell Endocrinol. 324:87–94. 2010. View Article : Google Scholar : PubMed/NCBI
28	Sauter M, Sigl J, Schotten KJ, Kreuzer L, Günthner-Biller M and Fischereder M: Use of oestrogen-containing medication is not associated with renal angiomyolipoma in tuberous sclerosis: Findings from a survey. Int Urol Nephrol. 47:707–708. 2015. View Article : Google Scholar : PubMed/NCBI
29	Huang KH, Huang CY, Chung SD, Pu YS, Shun CT and Chen J: Malignant epithelioid angiomyolipoma of the kidney. J Formos Med Assoc. 106 2 Suppl:S51–S54. 2007. View Article : Google Scholar : PubMed/NCBI
30	Kavaney PB and Fielding I: Angiomyolipoma and renal cell carcinoma in same kidney. Urology. 6:643–646. 1975. View Article : Google Scholar : PubMed/NCBI
31	Corsenca A, Aebersold F, Moch H, Bird P, Weber M, Hofbauer G, Wüthrich RP and Serra AL: Combined nephrectomy and pre-emptive renal transplantation in a tuberous sclerosis patient with angiomyolipoma, renal carcinoma and life-threatening abdominal haemorrhages. Nephrol Dial Transplant. 22:3330–3333. 2007. View Article : Google Scholar : PubMed/NCBI
32	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
33	Eble JN: Angiomyolipoma of kidney. Semin Diagn Pathol. 15:21–40. 1998.PubMed/NCBI
34	Cichocki M, Sosnowski M and Jablonowski Z: A giant renal angiomyolipoma (AML) in a patient with septo-optic dysplasia (SOD). Eur J Med Res. 19:462014. View Article : Google Scholar : PubMed/NCBI
35	Hussain M, Mubarak M, Sultan G, Sultan G, Ahmed E, Yunus M, Salehi MA, Asif M, Naqvi Anwer SA and Rizvi SA: Renal transplant in a tuberous sclerosis patient with bilateral giant renal angiomyolipomas and concurrent renal carcinoma. Saudi J Kidney Dis Transpl. 24:318–321. 2013. View Article : Google Scholar : PubMed/NCBI
36	Taneja R and Singh DV: Giant renal angiomyolipoma: Unusual cause of huge abdominal mass. J Clin Imaging Sci. 3:562013. View Article : Google Scholar : PubMed/NCBI
37	Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T and Nakamura Y: Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res. 10:591–594. 1998.PubMed/NCBI
38	Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M and Takeda K: Renal angiomyolipoma: Relationships between tumor size, aneurysm formation, and rupture. Radiology. 225:78–82. 2002. View Article : Google Scholar : PubMed/NCBI
39	Mitra A, Jain Kumar S, Gupta D and Chandra Murthy Kaza R: Giant angiomyolipoma of the kidney presenting as anaemia-a rare presentation. Open J Urol. 2:75–77. 2012. View Article : Google Scholar
40	Curatolo P, Bombardieri R and Jozwiak S: Tuberous sclerosis. Lancet. 372:657–668. 2008. View Article : Google Scholar : PubMed/NCBI
41	Yang G, Yang L, Yang X, Shi X, Wang J, Liu Y, Ju J and Zou L: Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis. Exp Ther Med. 9:626–630. 2015.PubMed/NCBI
42	Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 358:140–151. 2008. View Article : Google Scholar : PubMed/NCBI
43	Cabrera-López C, Martí T, Catalá V, Torres F, Mateu S, Ballarín J and Torra R: Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: A two years trial. Orphanet J Rare Dis. 7:872012. View Article : Google Scholar : PubMed/NCBI
44	Peng ZF, Yang L, Wang TT, Han P, Liu ZH and Wei Q: Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: A systematic review. J Urol. 192:1424–1430. 2014. View Article : Google Scholar : PubMed/NCBI
45	Paul E and Thiele E: Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl J Med. 358:190–192. 2008. View Article : Google Scholar : PubMed/NCBI